{"nctId":"NCT00090259","briefTitle":"Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)","startDateStruct":{"date":"2001-12-19","type":"ACTUAL"},"conditions":["Heart Failure"],"count":3834,"armGroups":[{"label":"Losartan 50 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Losartan 50 mg"]},{"label":"Losartan 150 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Losartan 150 mg"]}],"interventions":[{"name":"Losartan 50 mg","otherNames":["Losartan potassium"]},{"name":"Losartan 150 mg","otherNames":["Losartan potassium"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Symptomatic heart failure with known or recently diagnosed intolerance of treatment with first-line medication for heart failure\n* May or may not be receiving an alternative and/or additional drug treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"889","spread":null},{"groupId":"OG001","value":"828","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants That Experienced One Components of the Composite Clinical Endpoint of All Cause Death or Cardiovascular Hospitalization","description":"Cardiovascular hospitalization is defined as any hospitalization that may be attributed to a cardiovascular cause, including heart failure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1085","spread":null},{"groupId":"OG001","value":"1037","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants That Died (Any Cause)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"665","spread":null},{"groupId":"OG001","value":"635","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants That Were Hospitalized for Heart Failure","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"503","spread":null},{"groupId":"OG001","value":"450","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants That Experienced Cardiovascular Hospitalization","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"826","spread":null},{"groupId":"OG001","value":"762","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":691,"n":1913},"commonTop":["Dizziness","Bronchitis","Blood creatinine increased","Cardiac failure","Blood urea increased"]}}}